Dynavax Technologies Corp. (Nasdaq: DVAX) reported upbeat Phase III results for its hepatitis B vaccine Heplisav sending the stock price soaring 45 cents to close at $1.86.
Dynavax Reports Upbeat Test Results
June 03, 2009 at 17:23 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.